{"name":"Shanghai Huilun Pharmaceutical Co., Ltd.","slug":"shanghai-huilun-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Silodosin capsules Control Group","genericName":"Silodosin capsules Control Group","slug":"silodosin-capsules-control-group","indication":"Benign prostatic hyperplasia (BPH)","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"H077 sustained-release tablet","genericName":"H077 sustained-release tablet","slug":"h077-sustained-release-tablet","indication":"Major depressive disorder","status":"phase_3"}]}],"pipeline":[{"name":"Silodosin capsules Control Group","genericName":"Silodosin capsules Control Group","slug":"silodosin-capsules-control-group","phase":"phase_3","mechanism":"Silodosin is an alpha-1 adrenergic receptor antagonist.","indications":["Benign prostatic hyperplasia (BPH)"],"catalyst":""},{"name":"H077 sustained-release tablet","genericName":"H077 sustained-release tablet","slug":"h077-sustained-release-tablet","phase":"phase_3","mechanism":"H077 sustained-release tablet is a medication that works by inhibiting the reuptake of a specific neurotransmitter.","indications":["Major depressive disorder"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNUGU2cnBHbDRqWVFkQkZuTklza24xTUllTkx2RGxNUEhoTHVDbDhDb1I0R0tWNnhPZG4zZGE5VTFTaWMwbXFXMElKYUFfUGNZc2hTb3ppanYyVUxNb1lyVm14M3F1OGRrMC0tOUxoY2czM3BXVWJTRHhmbVRxMzI0UFM2aXgzZmltZVBTWXFUWEE0RnNLUDRuTGNacXRuakdPTGc?oc=5","date":"2025-08-26","type":"pipeline","source":"BioWorld News","summary":"Haisco Pharmaceutical describes new Nav1.8 blockers for pain - BioWorld News","headline":"Haisco Pharmaceutical describes new Nav1.8 blockers for pain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE85UW1iQU1wMDZoSTBRLU9YOGpFc0xQQy1LNUxXTVJ5cUZHRmhlWUU2VGtOMHpfbVVIVzVxRDhFME5nWW1aZzhsUUpINFB4R0haMUVaNkRBekVueHhvSVRTNXl4WQ?oc=5","date":"2025-07-17","type":"pipeline","source":"Market.us","summary":"Factor Xa Inhibitors Market Size, Share | CAGR of 6.1% - Market.us","headline":"Factor Xa Inhibitors Market Size, Share | CAGR of 6.1%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPWVNzeHJxakhLOFRneGJpTHhjUXVudGNaWk1ueDdLbDNEQVhpVGs1N2VaVmFvdms5STMxMWtIUWE4NFp3VlZSZjJqVmk0ZHRPQndrTHV1MUNXRmxJYUdXRW44eXZTTzdWcUMtOHlCTXE0OUNnbE0yNjFSNmZhRHM2ZDRMNTUzRmlHdXRwVzlLa3RZcmZZN0JDbDU2VU9vTXFySmpTT3hyaUtHbnNsYVE?oc=5","date":"2025-02-19","type":"patent","source":"BioWorld News","summary":"Shanghai Wennai Pharmaceutical Technology patents new Nav1.8 blockers - BioWorld News","headline":"Shanghai Wennai Pharmaceutical Technology patents new Nav1.8 blockers","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}